Sfoglia per Rivista
SAFETY AND EFFICACY OF BORTEZOMIB IN RELAPSED MULTIPLE MYELOMA FOLLOWING REDUCED INTENSITY/NONMYELOABLATIVE CONDITIONINGS AND ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION
2006-01-01 L. Giaccone; R. Sorasio; F. Patriarca; D. Mattei; P. Corradini; V. Montefusco; J. Peccatori; R. Fanin; F. Carnevale-Schianca; S. Guidi; M.T. Petrucci; G. Milone; M. Rotta; B. Bruno; M. Boccadoro
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily
2014-01-01 T. P. Hughes;A. Hochhaus;H. M. Kantarjian;F. Cervantes;F. Guilhot;D. Niederwieser;P. D. le Coutre;G. Rosti;G. Ossenkoppele;C. Lobo;H. Shibayama;X. Fan;H. D. Menssen;C. Kemp;R. A. Larson;G. Saglio
Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials.
2013-01-01 Palumbo A1; Waage A; Hulin C; Beksac M; Zweegman S; Gay F; Gimsing P; Leleu X; Wijermans P; Sucak G; Pezzatti S; Juliusson G; Pégourié B; Schaafsma M; Galli M; Turesson I; Kolb B; van der Holt B; Baldi I; Rolke J; Ciccone G; Wetterwald M; Lokhorst H; Boccadoro M; Rodon P; Sonneveld P.
Screening of beta-thalassemia mutations by PCR and ASO analysis in an Italian population of mixed geographic origin.
1990-01-01 ALFARANO A.; GOTTARDI E.; SERRA A.; PIGA A.; MANDRINO M.; MAZZA U.; CAMASCHELLA C.
Screening selected blood donors with biochemical iron overload for hemochromatosis: a regional experience.
2004-01-01 M. De Gobbi;S. D'Antico;F. Castagno;D. Testa;R. Merlini;A. Bondi;C. Camaschella
se of peripheral blood stem cells to accelerate hemopoietic recovery following autologous bone marrow transplantation.
1990-01-01 Tarella C; Gavarotti P; Caracciolo D; Locatelli F; Falda M; Paolino F; Lovisone E; Sormano E; Tassi V; Urgesi A; et al.
SECOND GENERATION TYROSINE KINASE INHIBITORS CAN INDUCE COMPLETE MOLECULAR RESPONSE IN PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSING AFTER ALLOGENEIC STEM CELL TRANSPLANT
2010-01-01 Ulisciani S; Fava C; Falda M; Locatelli F;Busca A; D'Ardia S; Gottardi E; Daraio F; Giugliano E; Giaretto L; Saglio G; Rege Cambrin G
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: A phase II clinical trial of the fondazione italiana linfomi
2017-01-01 Zaja, Francesco; Ferrero, Simone; Stelitano, Caterina; Ferrari, Angela; Salvi, Flavia; Arcari, Annalisa; Musuraca, Gerardo; Botto, Barbara; Spina, Michele; Cellini, Claudia; Patti, Caterina; Liberati, Anna M.; Minotto, Claudia; Pileri, Stefano A.; Ceccarelli, Manuela; Volpetti, Stefano; Ferranti, Antonella; Drandi, Daniela; Montechiarello, Elisa; Ladetto, Marco; Carmichael, James; Fanin, Renato
Secondary myelodisplastic syndromes in childhood: a diagnostic suirveillance protocol
2005-01-01 Farinasso L.; Garbarini L.; Saracco P.; Crescenzio N.; Basso M.E.; Aschero S.; Doria A.; Iavarone A; Linari A.; Gottardi E.; Ramenghi U.; Cordero di Montezemolo L.; Timeus F.
SELINEXOR (KPT-330) IN COMBINATION WITH CHEMOTHERAPY OR IDELALISIB ELICITS A SYNERGISTIC CYTOTOXIC EFFECT IN PRIMARY CLL CELLS, ALSO OVERCOMING INTRINSIC AND STROMAL CELLS-MEDIATED FLUDARABINE RESISTANCE
2018-01-01 Todaro, M; Griggio, V; Vitale, C; Salvetti, C; Riganti, C; Boccadoro, M; Coscia, M
Serological Proteome Analysis (SERPA) as a tool for the identification of novel tumor antigens in chronic lymphocytic leukemia (CLL)
2012-01-01 Valentina Griggio; Michela Capello; Candida Vitale; Federica Linty; Paola Cappello; Giorgia Mandili; Barbara Castella; Myriam Foglietta; Micol Rigoni; Patrizia Sciancalepore; Daniela Drandi; Marina Ruggeri; Paola Omedé; Marco Ladetto; Francesco Novelli; Mario Boccadoro; Massimo Massaia; Marta Coscia
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA
2011-01-01 M. Coscia; V. Griggio; M. Capello; F. Linty; C. Vitale; S. Peola; P. Cappello; B. Castella; M. Rigoni; P. Sciancalepore; D. Drandi; M. Ruggeri; P. Omedè; M. Ladetto; F. Novelli; M. Boccadoro; M. Massaia
Serum erythropoietin and circulating transferrin receptor in thalassemia intermedia patients with heterogeneous genotypes
1996-01-01 Camaschella, C; Gonella, S; Calabrese, R; Vischia, F; Roetto, A; Graziadei, G; Mazza, U; Cappellini, M D
SERUM FREE LIGHT CHAINS (SFLC) ASSAY: A SUGGESTIVE NEW CRITERIA FOR EVALUATING DISEASE RESPONSE, PROGRESSION AND RELAPSE IN PLASMA-CELL DISORDERS (PD) AND A PROGNOSTIC FACTOR IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS)
2006-01-01 Giarin MM; Giaccone L; Caracciolo D; Bruno B; Falco P; Omedè P; Battaglio S; Hila I; Sfiligoi C; Fiore F; Amoroso B; Boccadoro M
Simultaneous expression of CD38 and its ligand CD31 by chronic lymphocytic leukemia B-cells: anecdotal observation or pathogenetic hypothesis for the clinical outcome?
2003-01-01 F. MORABITO; M. MANGIOLA; C. STELITANO; S. DEAGLIO; V. CALLEA; F. MALAVASI
Simultaneous occurrence of hairy cell leukemia and Hodgkin's disease in the same patient.
1985-01-01 RESEGOTTI L ;PISTONE M ;TESTA D ;RUÀ S ;CODA R
Single tube melting temperature assay for rapid and sensitive detection of the most frequent hemocromatosis mutations, C282Y and H63D
2000-01-01 Marziliano N.; Bevilacqua E.; Pirulli D.; Spano A.; Amoroso A.; Crovella S.
SLAMF1/CD150 IS A SIGNALING RECEPTOR EXPRESSED BY A SUBSET OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS CHARACTERIZED BY A FAVORABLE PROGNOSIS
2012-01-01 Bologna C; Buonincontri R; Serra S; Vaisitti T; Audrito V; Brusa D; Rossi D; Coscia M; Gaidano G; Terhorst C; Deaglio S
Socio-demographic and clinical determinants of patient-reported symptom severity in chronic myeloid leukemia survivors in treatment with imatinib over the long run.
2011-01-01 F. Efficace; F. Castagnetti; M. Breccia; G. Alimena; F. Cottone; G. Rosti; G. Lambertenghi Deliliers; C. Baratè; A. Russo Rossi; G. Fioritoni; L. Luciano; D. Turri; F. Nobile; F. Di Raimondo; F. Cavazzini; M. Bergamaschi; P. Leoni; M. Simula; L. Levato; C. Fava; G. Pizzolo; S. Sica; A. Rambaldi; S. Pardini; F. Gherlinzoni; M. Salvucci; M. Tiribelli; M. Vignetti; F. Mandelli.
SODIUM VALPROATE ENHANCES IMATINIB INDUCED APOPTOSIS AND GROWTH ARREST IN BCR-ABL CELL LINES
2004-01-01 Morotti A; Cilloni D; Pautasso M; Baraban D; Messa F; Arruga F; De Filippi I; Messa E; Carturan S; Rege-cambrin G; Pilatrino C; Guerrasio A; Gottardi E; Saglio G
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| SAFETY AND EFFICACY OF BORTEZOMIB IN RELAPSED MULTIPLE MYELOMA FOLLOWING REDUCED INTENSITY/NONMYELOABLATIVE CONDITIONINGS AND ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION | 2006 | L. Giaccone; R. Sorasio; F. Patriarca; D. Mattei; P. Corradini; V. Montefusco; J. Peccatori; R. Fanin; F. Carnevale-Schianca; S. Guidi; M.T. Petrucci; G. Milone; M. Rotta; B. Bruno; M. Boccadoro | |
| Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily | 2014 | T. P. Hughes;A. Hochhaus;H. M. Kantarjian;F. Cervantes;F. Guilhot;D. Niederwieser;P. D. le Coutre;G. Rosti;G. Ossenkoppele;C. Lobo;H. Shibayama;X. Fan;H. D. Menssen;C. Kemp;R. A. Larson;G. Saglio | |
| Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. | 2013 | Palumbo A1; Waage A; Hulin C; Beksac M; Zweegman S; Gay F; Gimsing P; Leleu X; Wijermans P; Sucak G; Pezzatti S; Juliusson G; Pégourié B; Schaafsma M; Galli M; Turesson I; Kolb B; van der Holt B; Baldi I; Rolke J; Ciccone G; Wetterwald M; Lokhorst H; Boccadoro M; Rodon P; Sonneveld P. | |
| Screening of beta-thalassemia mutations by PCR and ASO analysis in an Italian population of mixed geographic origin. | 1990 | ALFARANO A.; GOTTARDI E.; SERRA A.; PIGA A.; MANDRINO M.; MAZZA U.; CAMASCHELLA C. | |
| Screening selected blood donors with biochemical iron overload for hemochromatosis: a regional experience. | 2004 | M. De Gobbi;S. D'Antico;F. Castagno;D. Testa;R. Merlini;A. Bondi;C. Camaschella | |
| se of peripheral blood stem cells to accelerate hemopoietic recovery following autologous bone marrow transplantation. | 1990 | Tarella C; Gavarotti P; Caracciolo D; Locatelli F; Falda M; Paolino F; Lovisone E; Sormano E; Tassi V; Urgesi A; et al. | |
| SECOND GENERATION TYROSINE KINASE INHIBITORS CAN INDUCE COMPLETE MOLECULAR RESPONSE IN PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSING AFTER ALLOGENEIC STEM CELL TRANSPLANT | 2010 | Ulisciani S; Fava C; Falda M; Locatelli F;Busca A; D'Ardia S; Gottardi E; Daraio F; Giugliano E; Giaretto L; Saglio G; Rege Cambrin G | |
| Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: A phase II clinical trial of the fondazione italiana linfomi | 2017 | Zaja, Francesco; Ferrero, Simone; Stelitano, Caterina; Ferrari, Angela; Salvi, Flavia; Arcari, Annalisa; Musuraca, Gerardo; Botto, Barbara; Spina, Michele; Cellini, Claudia; Patti, Caterina; Liberati, Anna M.; Minotto, Claudia; Pileri, Stefano A.; Ceccarelli, Manuela; Volpetti, Stefano; Ferranti, Antonella; Drandi, Daniela; Montechiarello, Elisa; Ladetto, Marco; Carmichael, James; Fanin, Renato | |
| Secondary myelodisplastic syndromes in childhood: a diagnostic suirveillance protocol | 2005 | Farinasso L.; Garbarini L.; Saracco P.; Crescenzio N.; Basso M.E.; Aschero S.; Doria A.; Iavarone A; Linari A.; Gottardi E.; Ramenghi U.; Cordero di Montezemolo L.; Timeus F. | |
| SELINEXOR (KPT-330) IN COMBINATION WITH CHEMOTHERAPY OR IDELALISIB ELICITS A SYNERGISTIC CYTOTOXIC EFFECT IN PRIMARY CLL CELLS, ALSO OVERCOMING INTRINSIC AND STROMAL CELLS-MEDIATED FLUDARABINE RESISTANCE | 2018 | Todaro, M; Griggio, V; Vitale, C; Salvetti, C; Riganti, C; Boccadoro, M; Coscia, M | |
| Serological Proteome Analysis (SERPA) as a tool for the identification of novel tumor antigens in chronic lymphocytic leukemia (CLL) | 2012 | Valentina Griggio; Michela Capello; Candida Vitale; Federica Linty; Paola Cappello; Giorgia Mandili; Barbara Castella; Myriam Foglietta; Micol Rigoni; Patrizia Sciancalepore; Daniela Drandi; Marina Ruggeri; Paola Omedé; Marco Ladetto; Francesco Novelli; Mario Boccadoro; Massimo Massaia; Marta Coscia | |
| SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA | 2011 | M. Coscia; V. Griggio; M. Capello; F. Linty; C. Vitale; S. Peola; P. Cappello; B. Castella; M. Rigoni; P. Sciancalepore; D. Drandi; M. Ruggeri; P. Omedè; M. Ladetto; F. Novelli; M. Boccadoro; M. Massaia | |
| Serum erythropoietin and circulating transferrin receptor in thalassemia intermedia patients with heterogeneous genotypes | 1996 | Camaschella, C; Gonella, S; Calabrese, R; Vischia, F; Roetto, A; Graziadei, G; Mazza, U; Cappellini, M D | |
| SERUM FREE LIGHT CHAINS (SFLC) ASSAY: A SUGGESTIVE NEW CRITERIA FOR EVALUATING DISEASE RESPONSE, PROGRESSION AND RELAPSE IN PLASMA-CELL DISORDERS (PD) AND A PROGNOSTIC FACTOR IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS) | 2006 | Giarin MM; Giaccone L; Caracciolo D; Bruno B; Falco P; Omedè P; Battaglio S; Hila I; Sfiligoi C; Fiore F; Amoroso B; Boccadoro M | |
| Simultaneous expression of CD38 and its ligand CD31 by chronic lymphocytic leukemia B-cells: anecdotal observation or pathogenetic hypothesis for the clinical outcome? | 2003 | F. MORABITO; M. MANGIOLA; C. STELITANO; S. DEAGLIO; V. CALLEA; F. MALAVASI | |
| Simultaneous occurrence of hairy cell leukemia and Hodgkin's disease in the same patient. | 1985 | RESEGOTTI L ;PISTONE M ;TESTA D ;RUÀ S ;CODA R | |
| Single tube melting temperature assay for rapid and sensitive detection of the most frequent hemocromatosis mutations, C282Y and H63D | 2000 | Marziliano N.; Bevilacqua E.; Pirulli D.; Spano A.; Amoroso A.; Crovella S. | |
| SLAMF1/CD150 IS A SIGNALING RECEPTOR EXPRESSED BY A SUBSET OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS CHARACTERIZED BY A FAVORABLE PROGNOSIS | 2012 | Bologna C; Buonincontri R; Serra S; Vaisitti T; Audrito V; Brusa D; Rossi D; Coscia M; Gaidano G; Terhorst C; Deaglio S | |
| Socio-demographic and clinical determinants of patient-reported symptom severity in chronic myeloid leukemia survivors in treatment with imatinib over the long run. | 2011 | F. Efficace; F. Castagnetti; M. Breccia; G. Alimena; F. Cottone; G. Rosti; G. Lambertenghi Deliliers; C. Baratè; A. Russo Rossi; G. Fioritoni; L. Luciano; D. Turri; F. Nobile; F. Di Raimondo; F. Cavazzini; M. Bergamaschi; P. Leoni; M. Simula; L. Levato; C. Fava; G. Pizzolo; S. Sica; A. Rambaldi; S. Pardini; F. Gherlinzoni; M. Salvucci; M. Tiribelli; M. Vignetti; F. Mandelli. | |
| SODIUM VALPROATE ENHANCES IMATINIB INDUCED APOPTOSIS AND GROWTH ARREST IN BCR-ABL CELL LINES | 2004 | Morotti A; Cilloni D; Pautasso M; Baraban D; Messa F; Arruga F; De Filippi I; Messa E; Carturan S; Rege-cambrin G; Pilatrino C; Guerrasio A; Gottardi E; Saglio G |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile